| Patent Number |
Title Of Patent |
Date Issued |
| 7553816 |
p-amidobenzylethers in drug delivery agents |
June 30, 2009 |
| Compounds of the formulas LA.sub.n-Z-X--W.sub.wD and BZ-X--W.sub.wD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-imm |
| 7510711 |
Methods for the treatment of cancer using anti-CD40 antibodies |
March 31, 2009 |
| The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of C |
| 7498298 |
Monomethylvaline compounds capable of conjugation to ligands |
March 3, 2009 |
| Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. |
| 7498032 |
Methods for treating immune disorders or cancer with anti-CD40 antibodies |
March 3, 2009 |
| The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of C |
| 7491390 |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
February 17, 2009 |
| Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed |
| 7423116 |
Pentapeptide compounds and uses related thereto |
September 9, 2008 |
| Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieties, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reactio |
| 7256257 |
Pentapeptide compounds and uses related thereto |
August 14, 2007 |
| Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reacti |
| 7098308 |
Pentapeptide compounds and uses related thereto |
August 29, 2006 |
| Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reacti |
| 7091186 |
p-Amidobenzylethers in drug delivery agents |
August 15, 2006 |
| Compounds of the formulae LA.sub.n-Z-X--W.sub.wD and BZ-X--W.sub.wD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide residue; X is an aminobenzyl ether self-immolative spacer group; W is an optional second |
| 7090843 |
Recombinant anti-CD30 antibodies and uses thereof |
August 15, 2006 |
| The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cyto |
| 6946129 |
Recombinant anti-CD40 antibody and uses thereof |
September 20, 2005 |
| The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 |
| 6884869 |
Pentapeptide compounds and uses related thereto |
April 26, 2005 |
| Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reacti |
| 6843989 |
Methods for the treatment and prevention of cancer using anti-CD40 antibodies |
January 18, 2005 |
| The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 |
| 6838261 |
Nucleic acids encoding anti-CD40 proteins and methods of producing recombinant anti-CD40 protein |
January 4, 2005 |
| The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 |
